QualityStocks would like to highlight Advaxis, Inc., (OTCBB: ADXS), a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete an antigen/adjuvant fusion protein that is designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself.
In the company’s news yesterday,
Advaxis announced it has completed the enrollment of 40 patients for the second of three dose cohorts in the phase II study to assessment the safety and efficacy of ADXS-HPV for the treatment of intraepithelial neoplasia (CIN) 2/3.
Patients enrolled for cohort 2 were randomized 3:1 to ADXS-HPV (3 doses at 3.3×108 cfu) or placebo, which is six times higher than that administered in cohort 1.
Patients will undergo observation for six months after the last dose, after which they will undergo the standard of care surgery (LEEP) required for the treatment of this disease.
Once all patients have completed LEEP, the company will report study results.
“Advaxis continues to meet major milestones in our clinical development plan,” Dr. John Rothman, EVP of Science & Operations at Advaxis stated in the press release. “We look forward to assessing the results of the second cohort of this study and to advancing the development of ADXS-HPV for the treatment of HPV-associated diseases.”
The company in February 2012 announced the results from the first cohort of the trial, which consisted of 41 patients randomized 3:1 ADXS-HPV (3 doses at 5×107 cfu) or placebo. Results demonstrated that 29 percent of the patients experienced side effects that were related, or were possibly related, to the treatment; no serious adverse events were experienced; 52 percent of CIN 2/3 lesions regressed from CIN 2/3 to CIN 1 or normal in the ADXS-HPV arm; and 40 percent of CIN 2/3 lesions spontaneously regressed in the placebo arm.
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.